Print Page
Hepatocellular (Liver)
Lakeland Regional Medical Center
Clinical Trial #E1208:
-
Chemoembolization with or without an oral treatment drug (Sorafenib) for liver cancer that cannot be removed surgically.
-
Participants can have Cirrhosis and at least 1 lesion greater than 2 centimeters or an AFP greater than 400 and at least 1 lesion greater than 2 centimeters. Disease must be limited to the liver but must be less than 50% diseased. RFA is allowed if it was more than 4 weeks ago. Participants also include those who have Child-Pugh A or B7.
-
Exclusions include, but are not limited to: Detectable ascites on physical exam or main portal vein invasion.
Clinical Trial #C80802:
-
Oral treatment drug (Sorafenib) with or without an IV chemotherapy (Doxorubicin) for liver cancer that has spread and cannot be removed by surgery.
-
Participants must have measurable disease of at least 1 centimeter. Prior chemoembolization or radiation therapy treatment is allowed.
-
Exclusions include, but are not limited to: Uncontrolled hypertension, prior systemic therapies or allografts or arrythimias requiring treatment other than beta blockers.
